27 research outputs found

    Engano na administração de soro-vacinação para raiva. Emprego de esquema improvisado e sua avaliação: apresentação de um caso

    No full text
    We report on a female patient attacked by a dog that died 4 days later, who sough treatment 11 days after the accident.A serum vaccination schedule was indicated, to be started immediately with the administration of anti-rabies serum (9 ml, corresponding to 40 IU/Kg body weight) and a series of 10 doses of vaccine applied on consecutive days plus 3 booster doses applied at 10-day intervals, according to the regulations of the Health . Secretariat of the State of Sao Paulo. However, due to an error, 9 vaccine doses were iniatially applied at 3 different anatomical sites. The error was immediately discovered and it was decided to interrup treatment for a few days and to restart and complete it later; this was done only 8 days later. Serologic follow-up by the serum-neutralization test in cell culture revealed a fully satisfactory response greatly exceeding WHO recommendations in terms of levels, precocity and duration. The patient continued to be healthy by the 240th day after the accident, when she was observed for the last time before this publication.Apresentamos registro de caso de paciente agredida por cão que morreu 4 dias depois, e que se apresentou para tratamento 11 dias após o acidente. Foi indicado esquema de soro-vacinação a ser iniciado imediatamente com administração de soro anti-rábico (9ml, correspondente a 40 UI/Kg de peso) e série de 10 doses de vacina aplicadas em dias consecutivos e 3 doses de reforço, com 10 dias de intervalo, conforme normas da Secretaria da Saúde do Estado de São Paulo. Por engano, entretanto, foram aplicadas inicialmente 9 doses de vacina em 3 locais anatômicos diferentes. Verificado o erro de imediato, optamos pela suspensão do tratamento por alguns dias e sua reimplantação completa, o que só foi feito após 8 dias. O seguimento sorológico (pelas provas de soro-neutralização em cultura celular) evidenciou resposta inteiramente satisfatória, superando largamente em níveis, precocidade e duração as recomendações da OMS. A paciente permanecia sadia até o 240º dia após o acidente, quando foi observada pela última vez antes desta publicação

    Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases

    No full text
    Background and purposes: Anti-aquaporin 4 antibodies are specific markers for Devics disease. This study aimed to test if this high specificity holds in the context of a large spectrum of systemic autoimmune and non-autoimmune diseases. Methods: Anti-aquaporin-4 antibodies (NMO-IgG) were determined by indirect immunofluorescence (IIF) on mouse cerebellum in 673 samples, as follows: group I (clinically defined Devic's disease, n = 47); group II [ inflammatory/demyelinating central nervous system (CNS) diseases, n = 41]; group III (systemic and organ-specific autoimmune diseases, n = 250); group IV (chronic or acute viral diseases, n = 35); and group V (randomly selected samples from a general clinical laboratory, n = 300). Results: MNO-IgG was present in 40/47 patients with classic Devic's disease (85.1% sensitivity) and in 13/22 (59.1%) patients with disorders related to Devic's disease. The latter 13 positive samples had diagnosis of longitudinally extensive transverse myelitis (n = 10) and isolated idiopathic optic neuritis (n = 3). One patient with multiple sclerosis and none of the remaining 602 samples with autoimmune and miscellaneous diseases presented NMO-IgG (99.8% specificity). The autoimmune disease subset included five systemic lupus erythematosus individuals with isolated or combined optic neuritis and myelitis and four primary Sjogren's syndrome (SS) patients with cranial/peripheral neuropathy. Conclusions: The available data clearly point to the high specificity of anti-aquaporin-4 antibodies for Devic's disease and related syndromes also in the context of miscellaneous non-neurologic autoimmune and non-autoimmune disorders.Research and Development Division, Fleury GroupResearch and Development Division, Fleury Grou

    Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases

    No full text
    Background and purposes: Anti-aquaporin 4 antibodies are specific markers for Devics disease. This study aimed to test if this high specificity holds in the context of a large spectrum of systemic autoimmune and non-autoimmune diseases.Methods: Anti-aquaporin-4 antibodies (NMO-IgG) were determined by indirect immunofluorescence (IIF) on mouse cerebellum in 673 samples, as follows: group I (clinically defined Devic's disease, n = 47); group II [ inflammatory/demyelinating central nervous system (CNS) diseases, n = 41]; group III (systemic and organ-specific autoimmune diseases, n = 250); group IV (chronic or acute viral diseases, n = 35); and group V (randomly selected samples from a general clinical laboratory, n = 300).Results: MNO-IgG was present in 40/47 patients with classic Devic's disease (85.1% sensitivity) and in 13/22 (59.1%) patients with disorders related to Devic's disease. the latter 13 positive samples had diagnosis of longitudinally extensive transverse myelitis (n = 10) and isolated idiopathic optic neuritis (n = 3). One patient with multiple sclerosis and none of the remaining 602 samples with autoimmune and miscellaneous diseases presented NMO-IgG (99.8% specificity). the autoimmune disease subset included five systemic lupus erythematosus individuals with isolated or combined optic neuritis and myelitis and four primary Sjogren's syndrome (SS) patients with cranial/peripheral neuropathy.Conclusions: the available data clearly point to the high specificity of anti-aquaporin-4 antibodies for Devic's disease and related syndromes also in the context of miscellaneous non-neurologic autoimmune and non-autoimmune disorders.Research and Development Division, Fleury GroupUniversidade Federal de São Paulo, Div Rheumatol, UNIFESP, BR-04023062 São Paulo, BrazilFleury Grp, Div Res & Dev, São Paulo, BrazilUniv São Paulo, Dept Neurol, São Paulo, BrazilUniversidade Federal de São Paulo, Div Rheumatol, UNIFESP, BR-04023062 São Paulo, BrazilWeb of Scienc
    corecore